Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

NCT01530256 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT01530256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01530256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Lead sponsor
CSL Behring
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2012
Completion date
March 31, 2013
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute gvhd